Chugai's Xeloda Obtains Additional Indications, Applies Tarceva For Pancreatic Cancer
This article was originally published in PharmAsia News
Executive Summary
The largest oncology drug maker in Japan, Roche's Japanese unit Chugai Pharmaceutical, obtained approvals for additional indications for anti-cancer drug Xeloda (capecitabine) and additional dosages for Avastin (bevacizumab). The company also submitted an application for an additional indication of pancreatic cancer for Tarceva (erlotinib), currently approved for non-small cell lung cancer in Japan
You may also be interested in...
Drug Makers Say Japan's PMDA Drug Review Performance Improving
Japan's drug review body, the Pharmaceutical and Medical Device Agency, has significantly improved performance of the drug review process, demonstrated by shortened review times and higher satisfaction ratings, said the Office of Pharmaceutical Industry Research, a policy think tank under the industry trade association Japan Pharmaceutical Manufacturers Association
Japan's MHLW Enhances Role Of Innovation In Drug Pricing, USTR Says
WASHINGTON - Japan is giving more weight to innovation when pricing new drugs
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).